WSC 2022 | WSC 2022 highlights: collateral flow in MR CLEAN-LATE

Ana Catarina Fonseca, MD, PhD, University of Lisbon, Lisbon, Portugal, highlights the findings of the MR CLEAN-LATE trial as a key development from the World Stroke Congress 2022. The MR CLEAN-LATE trial assessed the benefit of collateral flow assessment for selecting patients who may benefit from endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion (LVO) presenting beyond 6 hours. The study enrolled over 500 patients who showed any degree of collateral flow on CT angiography. The primary endpoint of the study was met, with EVT providing a significant benefit on modified Rankin Scale score (mRS) after 90 days, compared to no EVT (odds ratio 1.68). These findings demonstrate that the presence of collateral flow on CT angiography is an adequate criterion for patient selection in the late time window and raises the question of whether perfusion imaging is required in this setting. This interview took place at the World Stroke Congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.